Defining process design space for monoclonal antibody cell culture

The concept of design space has been taking root as a foundation of in‐process control strategies for biopharmaceutical manufacturing processes. During mapping of the process design space, the multidimensional combination of operational variables is studied to quantify the impact on process performance in terms of productivity and product quality. An efficient methodology to map the design space for a monoclonal antibody cell culture process is described. A failure modes and effects analysis (FMEA) was used as the basis for the process characterization exercise. This was followed by an integrated study of the inoculum stage of the process which includes progressive shake flask and seed bioreactor steps. The operating conditions for the seed bioreactor were studied in an integrated fashion with the production bioreactor using a two stage design of experiments (DOE) methodology to enable optimization of operating conditions. A two level Resolution IV design was followed by a central composite design (CCD). These experiments enabled identification of the edge of failure and classification of the operational parameters as non‐key, key or critical. In addition, the models generated from the data provide further insight into balancing productivity of the cell culture process with product quality considerations. Finally, process and product‐related impurity clearance was evaluated by studies linking the upstream process with downstream purification. Production bioreactor parameters that directly influence antibody charge variants and glycosylation in CHO systems were identified. Biotechnol. Bioeng. 2010;106: 894–905. © 2010 Wiley Periodicals, Inc.

[1]  Brian D. Kelley,et al.  Robustness Testing of a Chromatographic Purification Step Used in Recombinant Factor IX Manufacture , 1998 .

[2]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[3]  P. Hinckley,et al.  Host cell protein clearance during protein a chromatography: Development of an improved column wash step , 2008, Biotechnology progress.

[4]  R. Jefferis Glycosylation of Recombinant Antibody Therapeutics , 2008, Biotechnology progress.

[5]  James E. Seely,et al.  A rational, step-wise approach to process characterization , 2003 .

[6]  A A Shukla,et al.  Process characterization for metal‐affinity chromatography of an Fc fusion protein: a design‐of‐experiments approach , 2001, Biotechnology and applied biochemistry.

[7]  Steven Kozlowski,et al.  Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.

[8]  Anurag S. Rathore,et al.  Design space for biotech products , 2007 .

[9]  Martin Gawlitzek,et al.  Identification of cell culture conditions to control N‐glycosylation site‐occupancy of recombinant glycoproteins expressed in CHO cells , 2009, Biotechnology and bioengineering.

[10]  Xiangyang Wang,et al.  Defining Process Design Space for Biotech Products: Case Study of Pichia pastoris Fermentation , 2008, Biotechnology progress.

[11]  A. Rathore,et al.  Quality by Design: Industrial Case Studies on Defining and Implementing Design Space for Pharmaceutical Processes Part 1 , 2008 .

[12]  Jouko Yliruusi,et al.  Novel description of a design space for fluidised bed granulation. , 2007, International journal of pharmaceutics.

[13]  Jae-Jin Jeon,et al.  Effect of culture temperature on erythropoietin production and glycosylation in a perfusion culture of recombinant CHO cells , 2008, Biotechnology and bioengineering.

[14]  C. Hoy,et al.  Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator. , 2000, Biotechnology and bioengineering.

[15]  Steven L. Nail,et al.  Elements of Quality by Design in Development and Scale-Up of Freeze-Dried Parenterals , 2008 .

[16]  Feng Li,et al.  A Systematic Approach for Scale‐Down Model Development and Characterization of Commercial Cell Culture Processes , 2006, Biotechnology progress.